| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7745409 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(2 months ago) | |
| US7704947 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(2 months ago) | |
| US7371727 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(2 months ago) | |
| US8080526 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(2 months ago) | |
| US7304036 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Aug, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8110553 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(2 months ago) | |
| US8933030 | ABBVIE | Treatments for gastrointestinal disorders |
Feb, 2031
(6 years from now) | |
| US10702576 | ABBVIE | Stable formulations of linaclotide |
Aug, 2031
(7 years from now) | |
| US10675325 | ABBVIE | Stable formulations of linaclotide |
Aug, 2031
(7 years from now) | |
| US8802628 | ABBVIE | Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration |
Oct, 2031
(7 years from now) | |
| US8748573 | ABBVIE | Formulations comprising linaclotide |
Oct, 2031
(7 years from now) | |
| US9708371 | ABBVIE | Treatments for gastrointestinal disorders |
Aug, 2033
(9 years from now) | |
Linzess is owned by Abbvie.
Linzess contains Linaclotide.
Linzess has a total of 12 drug patents out of which 5 drug patents have expired.
Expired drug patents of Linzess are:
- US8110553
- US7745409
- US7704947
- US7371727
- US8080526
Linzess was authorised for market use on 30 August, 2012.
Linzess is available in capsule;oral dosage forms.
Linzess can be used as method of treating chronic idiopathic constipation in adult patients., treatment of functional constipation in pediatric patients 6 to 17 years of age, method of treating irritable bowel syndrome with constipation in adults, method of treating irritable bowel syndrome with constipation in adult patients..
Drug patent challenges can be filed against Linzess from 30 August, 2016.
The generics of Linzess are possible to be released after 16 August, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-921) | Jun 12, 2026 |
| New Strength(NS) | Jan 25, 2020 |
| New Chemical Entity Exclusivity(NCE) | Aug 30, 2017 |
Drugs and Companies using LINACLOTIDE ingredient
NCE-1 date: 30 August, 2016
Market Authorisation Date: 30 August, 2012
Treatment: Method of treating irritable bowel syndrome with constipation in adults; Treatment of functional constipation in pediatric patients 6 to 17 years of age; Method of treating irritable bowel syndrome wi...
Dosage: CAPSULE;ORAL
LINZESS family patents
